In the CDMO industry, discussions often revolve around what clients should look for in a partner. However, it is equally crucial to determine what CDMOs seek from their clients. While client checklists for selecting CDMOs are abundant, the perspective often neglects the reciprocal responsibilities. Discover why transparency is vital for both parties.
In Part 2 of our series, we delve deeper into the fundamental elements necessary for establishing trust and efficiency in client-CDMO collaborations. Join us as we navigate the complex landscape of CDMO partnerships and examine the significance of analytics, documentation, raw materials, equipment selection, and more.
Fostering strong relationships with clients is paramount for mutual success. As we delve into the final installment of our client checklist series, we reflect on the critical elements that contribute to a fruitful partnership between CDMOs and prospective clients, such as project management, decision-making, MSA negotiations, and building trust in CDMO-client partnerships.
Natural killer (NK) cells represent a promising avenue for cellular immunotherapy due to their inherent cytotoxic potential against tumor cells and virally infected cells. Examine the advantages of NK cells in cellular immunotherapy and the importance of developing efficient activation and expansion platforms.
Accurately quantifying viral titers is a challenge in the production of viral vectors. Physical titers often overestimate the number of viral particles, while functional titers provide more practical information on potency and quality. Delve into the pitfalls of flow cytometry analysis and uncover solutions to improve the accuracy of functional viral vector titration.
Theragent offers comprehensive services from research and development to manufacturing. Discover how we can provide value-added solutions for your challenging pre-clinical and clinical trial projects.
